Drug Approval | July 05, 2022
Sanofi flu vaccines licensed and approved for 2022-2023 influenza season
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Covaxin was earlier approved for children 12-18 years of age
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Subscribe To Our Newsletter & Stay Updated
